Evidence map›Paper›PMID 28158196›Full record

ArticlePloS one2017

Transcriptome-wide co-expression analysis identifies LRRC2 as a novel mediator of mitochondrial and cardiac function.

Chris McDermott-Roe, Marion Leleu, Glenn C Rowe, Oleg Palygin, John D Bukowy, Judy Kuo, Monika Rech, Steffie Hermans-Beijnsberger, Sebastian Schaefer, Eleonora Adami and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 6 countries.

Chris McDermott-RoeCardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States of America.ORCID http://orcid.org/0000-0002-2265-8140
Marion LeleuSchool of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Glenn C RoweDivision of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, United States of America.
Oleg PalyginCardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States of America.
John D BukowyCardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Judy KuoCardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Monika RechCenter for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
Steffie Hermans-BeijnsbergerCenter for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
Sebastian SchaeferNational Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.
Eleonora AdamiCardiovascular and Metabolic Sciences, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Esther E CreemersExperimental Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Matthias HeinigInstitute of Computational Biology, Helmholtz Zentrum München, Neuherberg, Germany.
Blanche SchroenCenter for Heart Failure Research, Department of Cardiology, CARIM School for Cardiovascular Diseases, Maastricht University, Maastricht, The Netherlands.
Zoltan AranyCardiovascular Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Enrico PetrettoMRC Clinical Sciences Centre, Imperial College London, London, UK, Duke-NUS Graduate Medical School, Singapore, Singapore.
Aron M GeurtsCardiovascular Center, Medical College of Wisconsin, Milwaukee, WI, United States of America.
Medical College of Wisconsin · USMaastricht University · NLAmsterdam UMC Location University of Amsterdam · NLCardiovascular Institute of the South · USDuke-NUS Medical School · SGÉcole Polytechnique Fédérale de Lausanne · CHHelmholtz Zentrum München · DEMax Delbrück Center · DENational Heart Centre Singapore · SGUniversity of Alabama at Birmingham · US

Funding

Advanced genetic engineering technology developmentDP2OD008396 · OD · MEDICAL COLLEGE OF WISCONSIN · PI GEURTS, ARON M · 2011 to 2011
$2.3M
Medical Research Council MC_U120097112NIH HHS DP2 OD008396
6 · The paper itself

Abstract

Mitochondrial dysfunction contributes to myriad monogenic and complex pathologies. To understand the underlying mechanisms, it is essential to define the full complement of proteins that modulate mitochondrial function. To identify such proteins, we performed a meta-analysis of publicly available gene expression data. Gene co-expression analysis of a large and heterogeneous compendium of microarray data nominated a sub-population of transcripts that whilst highly correlated with known mitochondrial protein-encoding transcripts (MPETs), are not themselves recognized as generating proteins either localized to the mitochondrion or pertinent to functions therein. To focus the analysis on a medically-important condition with a strong yet incompletely understood mitochondrial component, candidates were cross-referenced with an MPET-enriched module independently generated via genome-wide co-expression network analysis of a human heart failure gene expression dataset. The strongest uncharacterized candidate in the analysis was Leucine Rich Repeat Containing 2 (LRRC2). LRRC2 was found to be localized to the mitochondria in human cells and transcriptionally-regulated by the mitochondrial master regulator Pgc-1α. We report that Lrrc2 transcript abundance correlates with that of β-MHC, a canonical marker of cardiac hypertrophy in humans and experimentally demonstrated an elevation in Lrrc2 transcript in in vitro and in vivo rodent models of cardiac hypertrophy as well as in patients with dilated cardiomyopathy. RNAi-mediated Lrrc2 knockdown in a rat-derived cardiomyocyte cell line resulted in enhanced expression of canonical hypertrophic biomarkers as well as increased mitochondrial mass in the context of increased Pgc-1α expression. In conclusion, our meta-analysis represents a simple yet powerful springboard for the nomination of putative mitochondrially-pertinent proteins relevant to cardiac function and enabled the identification of LRRC2 as a novel mitochondrially-relevant protein and regulator of the hypertrophic response.

Indexed as

AnimalsHeart FailureHeat-Shock ProteinsHumansLeucine-Rich Repeat Serine-Threonine Protein Kinase-2MitochondriaMitochondrial ProteinsMyocytes, CardiacRatsTranscription FactorsTranscriptomeHeat-Shock ProteinsLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Mitochondrial ProteinsTranscription Factors

Identifiers

PMID28158196
PMCPMC5291451
OpenAlexW2583285365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.